The Journal of Neuroscience, January 24, 2007, 27(4):845-851; doi:10.1523/JNEUROSCI.3115-06.2007
Previous Article | Next Article 
Behavioral/Systems/Cognitive
Identification of Atropine- and P2X1 Receptor Antagonist-Resistant, Neurogenic Contractions of the Urinary Bladder
Charles Kennedy,
Paul N. Tasker,
Gemma Gallacher, and
Timothy D. Westfall
Division of Physiology and Pharmacology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 ONR, United Kingdom
Correspondence should be addressed to Dr. C. Kennedy, Division of Physiology and Pharmacology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow G4 ONR, UK. Email: c.kennedy{at}strath.ac.uk
Acetylcholine and ATP are excitatory cotransmitters in parasympathetic nerves. We used P2X1 receptor antagonists to further characterize the purinergic component of neurotransmission in isolated detrusor muscle of guinea pig urinary bladder. In the presence of atropine (1 µM) and prazosin (100 nM), pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) (0.1100 µM) and suramin (1300 µM) inhibited contractions evoked by 4 Hz nerve stimulation in a concentration-dependent manner (IC50 of 6.9 and 13.4 µM, respectively). Maximum inhibition was 5060%, which was unaffected by coadministration of the ectonucleotidase inhibitor ARL67156 (6-N,N-diethyl-D-ß,
-dibromomethyleneATP) (100 µM). The remaining responses were abolished by tetrodotoxin (1 µM). PPADS and suramin also reduced contractions to exogenous ATP (300 µM) by 4050%, but abolished those to the P2X1 agonist
,ß-methyleneATP (
,ß-meATP) (1 µM). The P2X1 antagonists reactive blue 2, NF279 (8,8'-[carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino)] bis-1,3,5-naphthalenetrisulfonic acid), MRS2159 (pyridoxal-
5-phosphate-6-phenylazo-4'-carboxylic acid) (100 µM), and NF449 [4,4',4,4-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid] (3 µM) abolished contractions to
,ß-meATP (1 µM; n = 45), but only reduced contractions evoked by 4 Hz nerve stimulation by
4060% (n = 46) and ATP by 3060% (n = 47). However, prolonged exposure to
,ß-meATP (50 µM) abolished contractions evoked by all three stimuli (n = 512). PPADS (100 µM) and suramin (300 µM) reduced the peak neurogenic contraction of the mouse urinary bladder to 3040% of control. At the same concentrations, the P2X1 antagonists abolished the nonadrenergic, purinergic component of neurogenic contractions in the guinea pig vas deferens (n = 45). Thus, P2X1 receptor antagonists inhibit, but do not abolish, the noncholinergic component of neurogenic contractions of guinea pig and mouse urinary bladder, indicating a second mode of action of neuronally released ATP. This has important implications for treatment of dysfunctional urinary bladder, for which this atropine- and P2X1 antagonist-resistant site represents a novel therapeutic target.
Key words: parasympathetic; urinary bladder; noncholinergic; ATP; P2X1 receptor; P2X4 receptor
Received July 21, 2006;
revised Dec. 8, 2006;
accepted Dec. 15, 2006.
Correspondence should be addressed to Dr. C. Kennedy, Division of Physiology and Pharmacology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow G4 ONR, UK. Email: c.kennedy{at}strath.ac.uk
This article has been cited by other articles:

|
 |

|
 |
 
F. J. Ehlert, S. Ahn, K. J. Pak, G. J. Park, M. S. Sangnil, J. A. Tran, and M. Matsui
Neuronally Released Acetylcholine Acts on the M2 Muscarinic Receptor to Oppose the Relaxant Effect of Isoproterenol on Cholinergic Contractions in Mouse Urinary Bladder
J. Pharmacol. Exp. Ther.,
August 1, 2007;
322(2):
631 - 637.
[Abstract]
[Full Text]
[PDF]
|
 |
|